Logo-jrip
Submitted: 02 Apr 2019
Accepted: 10 Jun 2019
ePublished: 30 Jun 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2019;8(3): 190-194.
doi: 10.15171/jrip.2019.35
  Abstract View: 560
  PDF Download: 463

Mini-Review

Administration of metformin in renal transplant patients with post-transplant diabetes mellitus 

Masoumeh Asgharpour 1, Seyed Hadi Mirhashemi 2, Amirhesam Alirezaei 3 *

1 Department of Nephrology, Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran
2 Department of Surgery, Loghman hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Urology and Nephrology Research Center, Shahid Modarres Hospital, Shahid-Beheshti University of Medical Sciences, Tehran, Iran
*Corresponding author: Amirhesam Alirezaei, Email: amirhesam124@gmail.com and Aalirezaei@sbmu.ac.ir

Abstract

Diabetes is the most common cause of renal failure which is frequently seen in candidates of solid organ transplant both before and after of the transplantation. For successful long-term tissue graft, it is important to control blood glucose level particularly after transplantation. Post-transplant diabetes mellitus (PTDM) is the main issue contributing to cardiovascularrelated mortality in kidney transplant recipients. Important risk factors of PTDM include using immunosuppressive drugs, post-transplant weight gain and obesity, and the presence of pre-transplant diabetes. Because of safety concerns, there has been a consensus from 2003 onward to cease metformin as the first-line anti-diabetic drug in patients with PTDM. The relationship between PTDM and metformin administration in high-risk renal transplant patients needs to be validated by more trial studies to establish the risk-benefit balance using this drug. Here, we reviewed the pros and cons of using metformin by presenting conclusions from several retrospective and clinical trial studies.
Keywords: Post-transplant diabetes mellitus, New-onset diabetes after transplantation, Diabetes mellitus, Transplantation, Immunosuppressive drugs, Obesity

Implication for health policy/practice/research/medical education:

Metformin is a safe and tolerable drug within one year after renal transplantation encouraging clinicians to administer this drug to renal transplant candidates.

Please cite this paper as: Asgharpour M, Mirhashemi SH, Alirezaei A. Administration of metformin in renal transplant patients with post-transplant diabetes mellitus. J Renal Inj Prev. 2019;8(3):190-194. DOI: 10.15171/jrip.2019.35. 

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 560

Your browser does not support the canvas element.


PDF Download: 463

Your browser does not support the canvas element.